ClinicalTrials.gg
RecruitingNCT06088134Updated May 31, 2025

Contrast-enhanced CT-based Deep Learning Model for Preoperative Prediction of Disease-free Survival (DFS) in Localized Clear Cell Renal Cell Carcinoma (ccRCC)

An observational study in Clear Cell Renal Cell Carcinoma, Prognostic Cancer Model and Recurrent Renal Cell Cancer, sponsored by Mingzhao Xiao. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2025-05-31.

Sponsored by Mingzhao Xiao · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started Sep 2022; still recruiting 4 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
800
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 235 studies in Carcinoma, Renal Cell with a site in China — 112 open to participants now, 142 under way, 10 of them phase 3. Carcinoma, Renal Cell · China.

Planned enrollment
11th of 45
800 · median 300
Started
2022
with 21 others
Observational
45 of 235
25 open now
Primary completion
2025-06
later than 18 of 141 live
Registered
120th of 235
by date

Among the 235 studies in Carcinoma, Renal Cell with a site in China, this one is the 11th largest by planned enrollment of the 45 observational ones that give a count, is one of 22 that started in 2022, is one of 45 observational ones, reaches primary completion later than 18 of the 141 other live ones, and was the 120th registered.

Carcinoma, Renal Cell

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

112 of the 235 studies in Carcinoma, Renal Cell with a site in China are open now. Recruiting first, the newest first:

107 more — sign in →

All 112 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 308 Carcinoma, Renal Cell studies recruiting now, 255 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 235 studies in Carcinoma, Renal Cell with a site in China, or all of them as a file.
02

Study summary

This study aims to preoperatively predict DFS of patients with localised ccRCC using a deep learning prognostic model based on enhanced contrast CT images, validate it's predictive ability in multicentre data and compare it's predictive ability with traditional models.

03

Conditions studied

  • Clear Cell Renal Cell Carcinoma
  • Prognostic Cancer Model
  • Recurrent Renal Cell Cancer
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients admitted to urology departments at participating medical centres

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • underwent partial/radical nephrectomies
  • diagnosed as ccRCC
  • with complete clinical data and preoperative CT image data

Exclusion criteria

Exclusion Criteria:

  • with incomplete clinic-pathological data
  • lack of preoperative contrast-enhanced CT images or the image quality was unsuitable for analysis
  • who received pre-surgery or adjuvant therapies
  • with multiple renal tumors or/and had synchronous
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
800 participants (estimated)
Patient registry
No

Groups and cohorts

  • Non-recurrence group
  • Recurrence group
06

What researchers measure

Primary outcomes

  1. disease-free survival (DFS)

    the interval from the date of surgery to disease recurrence, all-cause mortality or the last visit

    Time frame: recruitment occurred between June 2013 and March 2020

07

Study locations

1 of 1 sites recruiting
  • Yingjie Xv
    Chongqing, Chongqing Municipality 400016, China
    Recruiting
08

References and documents

Publications

  • Xv Y, Wei Z, Jiang Q, Zhang X, Chen Y, Xiao B, Yin S, Xia Z, Qiu M, Li Y, Tan H, Xiao M. Three-dimensional deep learning model complements existing models for preoperative disease-free survival prediction in localized clear cell renal cell carcinoma: a multicenter retrospective cohort study. Int J Surg. 2024 Nov 1;110(11):7034-7046. doi: 10.1097/JS9.0000000000001808. PubMed 38896853 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2022 (actual). Primary completion is estimated for Jun 2025, 33 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2023
First posted
Oct 18, 2023
StartActual
Sep 1, 2022
Primary completionEst.
Jun 1, 2025
CompletionEst.
Aug 1, 2025
Last update
May 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06088134
Lead sponsor
Mingzhao Xiao
Responsible party
Mingzhao Xiao (Urology Department, First Affiliated Hospital of Chongqing Medical University) — Sponsor-investigator
First posted
Oct 18, 2023
Start date
Sep 1, 2022
Primary completion
Jun 1, 2025 (estimated)
Completion
Aug 1, 2025 (estimated)
Last update
May 31, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion